» Articles » PMID: 19776069

No Evidence for Competition Between Cytotoxic T-lymphocyte Responses in HIV-1 Infection

Overview
Journal Proc Biol Sci
Specialty Biology
Date 2009 Sep 25
PMID 19776069
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Strong competition between cytotoxic T-lymphocytes (CTLs) specific for different epitopes in human immunodeficiency virus (HIV) infection would have important implications for the design of an HIV vaccine. To investigate evidence for this type of competition, we analysed CTL response data from 97 patients with chronic HIV infection who were frequently sampled for up to 96 weeks. For each sample, CTL responses directed against a range of known epitopes in gag, pol and nef were measured using an enzyme-linked immunospot assay. The Lotka-Volterra model of competition was used to predict patterns that would be expected from these data if competitive interactions materially affect CTL numbers. In this application, the model predicts that when hosts make responses to a larger number of epitopes, they would have diminished responses to each epitope and that if one epitope-specific response becomes dramatically smaller, others would increase in size to compensate; conversely if one response grows, others would shrink. Analysis of the experimental data reveals results that are wholly inconsistent with these predictions. In hosts who respond to more epitopes, the average epitope-specific response tends to be larger, not smaller. Furthermore, responses to different epitopes almost always increase in unison or decrease in unison. Our findings are therefore inconsistent with the hypothesis that there is competition between CTL responses directed against different epitopes in HIV infection. This suggests that vaccines that elicit broad responses would be favourable because they would direct a larger total response against the virus, in addition to being more robust to the effects of CTL escape.

Citing Articles

Defining Kinetic Properties of HIV-Specific CD8⁺ T-Cell Responses in Acute Infection.

Yang Y, Ganusov V Microorganisms. 2019; 7(3).

PMID: 30836625 PMC: 6462943. DOI: 10.3390/microorganisms7030069.


Sizing up the key determinants of the CD8(+) T cell response.

Tscharke D, Croft N, Doherty P, La Gruta N Nat Rev Immunol. 2015; 15(11):705-16.

PMID: 26449178 DOI: 10.1038/nri3905.


Evolutionary dynamics of HIV at multiple spatial and temporal scales.

Hill A, Rosenbloom D, Nowak M J Mol Med (Berl). 2012; 90(5):543-61.

PMID: 22552382 PMC: 7080006. DOI: 10.1007/s00109-012-0892-1.


Infection of HIV-specific CD4 T helper cells and the clonal composition of the response.

Roy S, Wodarz D J Theor Biol. 2012; 304:143-51.

PMID: 22480435 PMC: 4082790. DOI: 10.1016/j.jtbi.2012.03.015.


Modelling the spread of HIV immune escape mutants in a vaccinated population.

Fryer H, McLean A PLoS Comput Biol. 2011; 7(12):e1002289.

PMID: 22144883 PMC: 3228780. DOI: 10.1371/journal.pcbi.1002289.


References
1.
Moskophidis D, Zinkernagel R . Immunobiology of cytotoxic T-cell escape mutants of lymphocytic choriomeningitis virus. J Virol. 1995; 69(4):2187-93. PMC: 188887. DOI: 10.1128/JVI.69.4.2187-2193.1995. View

2.
Veiga-Fernandes H, Walter U, Bourgeois C, McLean A, Rocha B . Response of naïve and memory CD8+ T cells to antigen stimulation in vivo. Nat Immunol. 2001; 1(1):47-53. DOI: 10.1038/76907. View

3.
Grufman P, Wolpert E, Sandberg J, Karre K . T cell competition for the antigen-presenting cell as a model for immunodominance in the cytotoxic T lymphocyte response against minor histocompatibility antigens. Eur J Immunol. 1999; 29(7):2197-204. DOI: 10.1002/(SICI)1521-4141(199907)29:07<2197::AID-IMMU2197>3.0.CO;2-B. View

4.
Scherer A, Salathe M, Bonhoeffer S . High epitope expression levels increase competition between T cells. PLoS Comput Biol. 2006; 2(8):e109. PMC: 1550274. DOI: 10.1371/journal.pcbi.0020109. View

5.
Oxenius A, McLean A, Fischer M, Price D, Dawson S, Hafner R . Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy. J Virol. 2002; 76(20):10169-76. PMC: 136545. DOI: 10.1128/jvi.76.20.10169-10176.2002. View